Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II High Pulse Dose Trial of ITF 2357 in Relapsed/Refractory Multiple Myeloma
2008-001416-20Phase 2Terminated
- Sponsor
- Italfarmaco
- Start
- May 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givinostat in multiple myeloma (MM), sponsored by Italfarmaco. Primary endpoint: Primary safety endpoint. Started May 2008; status: terminated.
02
Drugs
givinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-001416-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001416-20.